Bendamustine Hydrochloride

Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular lymphoma who have received at least one prior line of treatment Data reinforce the potential of this Lunsumio-based regimen to improve clinical outcomes, while offering a tolerable safety profile, simple dosing schedule and outpatient administration Data will be submitted to health authorities and presented at an upcoming medical meeting SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the Phase III CELESTIMO study evaluating Lunsumio ® (mosunetuzumab-axgb) in combination with lenalidomide versus Rituxan ® (rituximab) plus lenalidomide in people with relapsed or refractory follicular lymphoma (FL) who have received at least one prior line of treatment met its primary endpoint. Results demonstrated a statistically significant and clinically meaningful improvement in progression-free survival. Overall survival data were immature at the time of interim analysis. The safety pro the Lunsumio and lenalidomide combination was consistent with the known profiles of the individual study medicines, with no new safety signals identified. Data from the study will be submitted to health authorities and presented at an upcoming medical meeting. “People living with relapsed or refractory follicular lymphoma need treatment options that provide meaningful clinical benefit and minimal disruptions to everyday care,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “The CELESTIMO results indicate that a two-drug outpatient Lunsumio regimen may offer these patients an effective new option earlier in their treatment journey.” CELESTIMO is a confirmatory study required to convert the accelerated approval/conditional marketing authorization of Lunsumio monotherapy for third-line or later (3L+) FL to full approval, as well as to secure an indication in second-line or later (2L+) FL. Lunsumio is part of Genentech’s industry-leading CD20xCD3 bispecific antibody program. It is designed with the unique needs and preferences of patients in mind, offering the possibility of outpatient treatment and flexibility between intravenous and subcutaneous administration routes. Lunsumio is already approved for people with 3L+ FL in 60 countries worldwide and has been used to treat over 3,800 patients. With the longest follow-up data of any bispecific antibody in lymphoma and a broad clinical development program spanning multiple disease settings, including both FL and diffuse large B-cell lymphoma (DLBCL), Lunsumio is helping redefine care across B-cell malignancies. The U.S. Food and Drug Administration recently accepted the supplemental Biologics License Application for Lunsumio in combination with Polivy ® (polatuzumab vedotin-piiq) for 2L+ DLBCL based on the SUNMO study, and results from CELESTIMO support continued expansion of Lunsumio and lenalidomide into earlier FL treatment, with the Phase III MorningLyte study ongoing in first-line FL. About the CELESTIMO study CELESTIMO [ NCT04712097 ] is a Phase III trial evaluating the efficacy and safety of Lunsumio ® (mosunetuzumab-axgb) in combination with lenalidomide vs. Rituxan ® (rituximab) plus lenalidomide in people with relapsed or refractory follicular lymphoma (FL) who have received at least one line of prior systemic therapy. It is a confirmatory study required to convert the accelerated approval/conditional marketing authorization of Lunsumio monotherapy for third-line or later FL to full approval, as well as to secure an indication in second-line or later FL. About follicular lymphoma (FL) Follicular lymphoma (FL) is the most common slow-growing (indolent) form of non-Hodgkin lymphoma, accounting for about one in five cases. It typically responds well to treatment but is often characterized by periods of remission and relapse. The disease typically becomes harder to treat each time a patient relapses, and early progression can be associated with poor long-term prognosis. It is estimated that, in the United States, more than 15,000 new cases of FL will be diagnosed in 2026, and more than 110,000 people are diagnosed with FL each year worldwide. About Lunsumio ® (mosunetuzumab-axgb) Lunsumio is a first-in-class CD20xCD3 T-cell-engaging bispecific antibody designed to target CD20 on the surface of B cells and CD3 on the surface of T cells. This dual-targeting activates and redirects a patient’s existing T cells to engage and eliminate target B cells by releasing cytotoxic proteins into the B cells. A robust clinical development program for Lunsumio is ongoing, investigating the molecule as a monotherapy and in combination with other medicines, for the treatment of people with B-cell non-Hodgkin lymphomas, including follicular lymphoma, diffuse large B-cell lymphoma, and other indications. About Polivy ® (polatuzumab vedotin-piiq) Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). The CD79b protein is expressed specifically in the majority of B cells, an immune cell impacted in some types of non-Hodgkin lymphoma (NHL), making it a promising target for the development of new therapies. Polivy binds to cancer cells such as CD79b and destroys these B cells through the delivery of an anti-cancer agent, which is thought to minimize the effects on normal cells. Polivy is being developed by Genentech using Pfizer ADC technology and is currently being investigated for the treatment of several types of NHL. Lunsumio and Lunsumio VELO U.S. Indication LUNSUMIO (mosunetuzumab-axgb) or LUNSUMIO VELO is a prescription medicine used to treat adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment, and who have already received two or more treatments. It is not known if LUNSUMIO or LUNSUMIO VELO is safe and effective in children. The conditional approval for this use is based on response rate. There are ongoing studies to establish how well the drug works. Important Safety Information What is the most important information I should know about LUNSUMIO or LUNSUMIO VELO? LUNSUMIO or LUNSUMIO VELO can cause Cytokine Release Syndrome (CRS), a serious side effect that is common during treatment with LUNSUMIO or LUNSUMIO VELO, and can also be severe or life-threatening. Get medical help right away if you develop any signs or symptoms of CRS at any time, including: fever of 100.4°F (38°C) or higher chills low blood pressure fast or irregular heartbeat tiredness or weakness difficulty breathing headache confusion feeling anxious dizziness or light-headedness nausea vomiting Due to the risk of CRS, you will receive LUNSUMIO or LUNSUMIO VELO on a “step-up dosing schedule.” The step-up dosing schedule is when you receive smaller “step-up” doses before receiving higher doses of LUNSUMIO or LUNSUMIO VELO during your first cycle of treatment If your dose of LUNSUMIO or LUNSUMIO VELO is delayed for any reason, you may need to repeat the “step-up dosing schedule” You may receive medicines to help reduce your risk of CRS before your dose Your healthcare provider will check you for CRS during treatment with LUNSUMIO or LUNSUMIO VELO and may treat you in a hospital if you develop signs and symptoms of CRS. Your healthcare provider may temporarily stop or completely stop your treatment with LUNSUMIO or LUNSUMIO VELO, if you have severe side effects. What are the possible side effects of LUNSUMIO or LUNSUMIO VELO? LUNSUMIO or LUNSUMIO VELO can cause serious side effects, including: Neurologic problems. LUNSUMIO or LUNSUMIO VELO can cause serious and life-threatening neurologic problems. Your healthcare provider will check you for neurologic problems during treatment with LUNSUMIO or LUNSUMIO VELO. Your healthcare provider may also refer you to a healthcare provider who specializes in neurologic problems. Tell your healthcare provider right away if you develop any signs or symptoms of neurologic problems during or after treatment with LUNSUMIO or LUNSUMIO VELO, including: headache numbness and tingling of the arms, legs, hands, or feet dizziness confusion and disorientation difficulty paying attention or understanding things forgetting things or forgetting who or where you are trouble speaking, reading or writing sleepiness or trouble sleeping tremors loss of consciousness seizures muscle problems or muscle weakness loss of balance or trouble walking tiredness Serious infections. LUNSUMIO or LUNSUMIO VELO can cause serious infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment. Tell your healthcare provider right away if you develop any signs or symptoms of infection during treatment with LUNSUMIO or LUNSUMIO VELO, including: fever of 100.4°F (38°C) or higher cough chest pain tiredness shortness of breath painful rash sore throat pain during urination feeling weak or generally unwell Hemophagocytic lymphohistiocytosis (HLH). LUNSUMIO or LUNSUMIO VELO can cause overactivity of the immune system, a condition called hemophagocytic lymphohistiocytosis. HLH can be life-threatening and has led to death in people treated with LUNSUMIO or LUNSUMIO VELO. Your healthcare provider will check you for HLH especially if your CRS lasts longer than expected. Signs and symptoms of HLH include: fever enlarged spleen easy bruising low blood cell counts liver problems Low blood cell counts. Low blood cell counts are common during treatment with LUNSUMIO or LUNSUMIO VELO and can also be serious or severe. Your healthcare provider will check your blood cell counts during treatment with LUNSUMIO or LUNSUMIO VELO. LUNSUMIO or LUNSUMIO VELO can cause the following low blood cell counts: low white blood cell counts (lymphopenia [for LUNSUMIO VELO only] and neutropenia). Low white blood cells can increase your risk for infection low red blood cell counts (anemia). Low red blood cells can cause tiredness and shortness of breath low platelet counts (thrombocytopenia). Low platelet counts can cause bruising or bleeding problems Growth in your tumor or worsening of tumor-related problems (tumor flare). LUNSUMIO or LUNSUMIO VELO can cause serious or severe worsening of your tumor. Tell your healthcare provider if you develop any of these signs or symptoms of tumor flare during your treatment with LUNSUMIO or LUNSUMIO VELO: chest pain cough trouble breathing tender or swollen lymph nodes pain or swelling at the site of the tumor Your healthcare provider may temporarily stop or permanently stop treatment with LUNSUMIO or LUNSUMIO VELO if you develop severe side effects. The most common side effects of LUNSUMIO include: CRS, tiredness, rash, headache, fever, muscle pain, cough, itching, and numbness, tingling, or pain in the hands or feet (nerve damage). The most common side effects of LUNSUMIO VELO include: injection site reactions, tiredness, rash, CRS, COVID-19, muscle and joint pain, and diarrhea. The most common severe abnormal blood test results with LUNSUMIO include: decreased phosphate, increased glucose, and increased uric acid levels. The most common severe abnormal blood test results with LUNSUMIO VELO include: decreased white blood cell counts and increased uric acid levels. Before receiving LUNSUMIO or LUNSUMIO VELO, tell your healthcare provider about all of your medical conditions, including if you: have ever had an infusion reaction after receiving LUNSUMIO have an infection or have had an infection in the past which lasted a long time or keeps coming back have or have had Epstein-Barr Virus are pregnant or plan to become pregnant. LUNSUMIO or LUNSUMIO VELO may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with LUNSUMIO or LUNSUMIO VELO Females who are able to become pregnant: your healthcare provider should do a pregnancy test before you start treatment with LUNSUMIO or LUNSUMIO VELO use an effective method of birth control (contraception) during your treatment and for 3 months after the last dose of LUNSUMIO or LUNSUMIO VELO are breastfeeding or plan to breastfeed. It is not known if LUNSUMIO or LUNSUMIO VELO passes into your breast milk. Do not breastfeed during treatment and for 3 months after the last dose of LUNSUMIO or LUNSUMIO VELO Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. What should I avoid while receiving LUNSUMIO or LUNSUMIO VELO? Do not drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, tremors, sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of CRS or neurologic problems. These are not all of the possible side effects of LUNSUMIO or LUNSUMIO VELO. Talk to your healthcare provider for more information about the benefits and risks of LUNSUMIO or LUNSUMIO VELO. You may report side effects to the FDA at (800) FDA-1088 or . You may also report side effects to Genentech at (888) 835-2555. Please see Important Safety Information, including Serious Side Effects, as well as the LUNSUMIO full Prescribing Information and Medication Guide and LUNSUMIO VELO full Prescribing Information and Medication Guide and on . Polivy U.S. Indication Polivy is a prescription medicine used with other medicines (a rituximab product, cyclophosphamide, doxorubicin, and prednisone) as a first treatment for adults who have moderate to high risk diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL). Polivy is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat DLBCL in adults who have progressed after at least 2 prior therapies. Important Safety Information Possible serious side effects Everyone reacts differently to Polivy therapy, so it’s important to know what the side effects are. Some people who have been treated with Polivy have experienced serious to fatal side effects. Your doctor may stop or adjust your treatment if any serious side effects occur. Be sure to contact your healthcare team if there are any signs of these side effects. Nerve problems in your arms and legs: This may happen as early as after your first dose and may worsen with every dose. Your doctor will monitor for signs and symptoms, such as changes in your sense of touch, numbness or tingling in your hands or feet, nerve pain, burning sensation, any muscle weakness, or changes to your walking pattern Infusion-related reactions: You may experience fever, chills, rash, breathing problems, low blood pressure, or hives within 24 hours of your infusion Low blood cell counts: Treatment with Polivy can cause severe low blood cell counts. Your doctor will monitor your blood counts throughout treatment with Polivy Infections: If you have a fever of 100.4°F (38°C) or higher, chills, cough, or pain during urination, contact your healthcare team. Your doctor may also give you medication before giving you Polivy, which may prevent some infections Rare and serious brain infections: Your doctor will monitor closely for signs and symptoms of these types of infections. Contact your doctor if you experience confusion, dizziness or loss of balance, trouble talking or walking, or vision changes Tumor lysis syndrome: Caused by the fast breakdown of cancer cells. Signs include nausea, vomiting, diarrhea, and lack of energy Potential harm to liver: Some signs include tiredness, weight loss, pain in the abdomen, dark urine, and yellowing of your skin or the white part of your eyes. You may be at higher risk if you already had liver problems or you are taking other medication Side effects seen most often The most common side effects during treatment were Nerve problems in arms and legs Nausea Tiredness or lack of energy Diarrhea Constipation Hair loss Redness and sores of the lining of the mouth, lips, throat, and digestive tract Polivy may lower your red or white blood cell counts and increase uric acid levels. Polivy may not be for everyone. Talk to your doctor if you are Pregnant or think you are pregnant: Data have shown that Polivy may harm your unborn baby Planning to become pregnant: Women should avoid getting pregnant while taking Polivy. Women should use effective contraception during treatment and for 3 months after their last Polivy treatment. Men taking Polivy should use effective contraception during treatment and for 5 months after their last Polivy treatment Breastfeeding: Women should not breastfeed while taking Polivy and for 2 months after the last dose These may not be all the side effects. Talk to your healthcare provider for more information about the benefits and risks of Polivy treatment. You may report side effects to the FDA at (800) FDA-1088 or . You may also report side effects to Genentech at (888) 835-2555. Please see the full Prescribing Information and visit for additional Important Safety Information. About Genentech Founded 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit . About Genentech in Hematology-Oncology Genentech has a comprehensive blood cancer portfolio, with approved and investigational treatment options spanning lymphomas, leukemias, and multiple myeloma. For more than 30 years, we’ve developed innovative therapies with novel mechanisms that have transformed the treatment landscape for people living with blood cancers. Our emphasis on developing fixed-duration and outpatient therapies is an important factor in bringing advanced medicines into community settings where most patients are treated. Working in lockstep with the full oncology ecosystem, we are helping to shape the next era of transformative hematology care for all who need it. Contacts Media Contact: Kristen Ingram (650) 467-6800 Advocacy Contact: Catherine Creme Henry (202) 258-8828 Investor Contacts: Loren Kalm (650) 225-3217 Bruno Eschli +41 61 687 5284

外周T细胞淋巴瘤（PTCL）是一组高度异质性的恶性淋巴瘤。与B细胞淋巴瘤相比，PTCL发病率相对较低，但亚洲国家的发病比例更高，而且不同亚型之间在疾病特点、治疗反应和预后方面存在明显差异。 近年来，随着新药和新的治疗策略不断出现，PTCL的治疗也在发生变化。本期“淋巴瘤大讲堂”，北京陆道培医院的柳喜洋教授围绕外周T细胞淋巴瘤的诊疗现状、一线治疗、复发难治治疗以及造血干细胞移植的选择进行了系统介绍。 视频讲解更精彩，请点击观看 外周T细胞淋巴瘤的诊疗现状 外周T细胞淋巴瘤总体发病率低于B细胞淋巴瘤，但在亚洲国家更为常见。近年来发病率呈逐渐升高趋势，但治愈率仍然相对较低。不同亚型之间的预后差异也非常明显。 目前PTCL治疗仍面临多重困境。治疗药物数量和治疗选择明显少于B细胞淋巴瘤。在诊断、临床研究以及创新疗法的可及性方面也存在挑战。 诊断困难 PTCL的生物标志物判读存在一定困难，部分指标缺乏统一的临界值标准，免疫组化检测工具也存在不足，其中，血管免疫母细胞T细胞淋巴瘤的诊断尤其困难，它在临床和病理表现上可能与B细胞淋巴瘤、霍奇金淋巴瘤、结核以及其他未明确分类的T细胞淋巴增殖性疾病等存在相似之处，建议有条件时应获取具有丰富经验的淋巴瘤病理专家的诊断意见。 创新治疗和临床试验较少 由于PTCL相对少见、亚型复杂，临床试验数量较B细胞淋巴瘤少，患者获得创新疗法的机会也受到一定限制。同时，监管流程、资金和研究资源、临床试验基础设施等因素，也会影响临床研究开展以及新药的进一步应用。 高度异质性的特点使临床研究更复杂 不同亚型的疾病预后不同，哪些患者最适合某一种创新药物，仍然缺少足够的数据支持。 外周T细胞淋巴瘤一线治疗：分层策略与重点进展 目前，PTCL一线治疗仍以CHOP为基础，但2026年CSCO指南强调不同PTCL亚型的一线治疗策略有所区别。 ALK阳性ALCL 总体预后较好，且多为CD30阳性，首选维布妥昔单抗联合CHP（A+CHP）。III～IV期均可采用；局限期可联合局部放疗。 其他PTCL 有条件者优先参加临床试验；CD30阳性者可考虑化疗联合维布妥昔单抗；部分患者可选DA-EPOCH等强化方案；局限期可联合放疗。一线达完全缓解（CR）者，可考虑自体造血干细胞移植巩固。 传统CHOP长期疗效有限，“CHOP+X”即化疗联合靶向药，是重要探索方向。 # CD30阳性患者：维布妥昔单抗联合CHP带来长期获益 ECHELON-2研究纳入452例初治PTCL患者，随机接受6～8周期A+CHP或CHOP。5年随访显示：A+CHP组PFS 51.4% vs 43.0%，OS 70.1% vs 61.0%；PFS HR 0.70，OS HR 0.72。该结果奠定了维布妥昔单抗在CD30阳性PTCL一线治疗中的地位。 中国真实世界研究中，BV-CHP治疗CD30阳性PTCL的ORR达96.2%，CR率75%。分亚型看，ALK阳性ALCL的ORR/CR为100%/71.4%，ALK阴性ALCL为95.5%/72.7%，AITL均为90%，PTCL-NOS为100%/66.7%。另一项纳入33例患者的研究显示，BV-CHP治疗ORR 91%，CR 76%，其中ALCL患者ORR 100%、CR 86%；中位随访29.6个月，2年PFS 78%、2年OS 90%。与传统CHOP方案相比，相关数据提示BV联合化疗有望进一步改善患者的PFS和OS。 # 新型靶向药联合CHOP：仍在探索 戈利昔替尼联合CHOP：150mg每日一次，可评估患者中16例客观缓解，11例CR，CR率61.1%，ORR 88.9%。需关注巨细胞病毒（CMV）感染风险，治疗期间定期监测并预防。 林普利塞联合CHOP：完成6周期后CR率56.4%～66.7%；最佳ORR 92.3%，最佳CR 66.7%；中位随访14.5个月，1年PFS 60.3%，1年OS 82.9%。其中血管免疫母细胞T细胞淋巴瘤和间变大细胞淋巴瘤的疗效相对较好。 不能耐受化疗的患者，能否采用“无化疗”方案？ 并非所有PTCL患者都能够耐受强化疗。对于年龄较大、身体状态较差或者存在其他因素、难以耐受传统化疗的虚弱患者，chemo-free（无化疗）方案也是目前探索的重要方向。 相关研究探索了戈利昔替尼联合阿扎胞苷和西达本胺治疗虚弱PTCL患者的疗效。截至2026年2月28日的数据截止时，中位随访时间为7.1个月，8例患者可以进行疗效评估，其中：4例达到CR；3例达到PR；1例为SD。3个周期后的ORR为87.5%，CR率为50%；在完成6个周期治疗并进行评估的4例患者中，2例达到CR，另2例出现疾病进展。 目前这项研究病例数仍然较少，但是这类探索提示，对于不能耐受传统化疗的虚弱PTCL患者，无化疗治疗模式可能成为新的治疗方向。 复发难治外周T细胞淋巴瘤：治疗仍是巨大挑战 如果PTCL进入复发或难治阶段，患者的预后会进一步恶化。相关数据显示，复发难治PTCL患者的2年PFS通常不超过30%。影响预后的因素包括：ECOG评分≥2、非结节性组织学类型、结外受累、骨髓受累、LDH水平升高。 目前临床上仍常使用PIT等预后评分体系对患者进行风险分层。新的预后指数也正在被探索，有望进一步区分不同风险患者，帮助制定更加精准的治疗策略。 2026年CSCO相关指南对于复发难治PTCL患者的治疗，主要根据患者是否具备移植条件进行分层。 # 有移植条件的患者 对于适合移植的复发难治PTCL患者，应积极争取获得疾病缓解，并考虑造血干细胞移植。 如果患者属于远期复发且对化疗敏感，可以考虑自体造血干细胞移植；但总体而言，对于复发难治PTCL，异基因造血干细胞移植通常更加值得考虑。 可选药物包括西达本胺、戈利昔替尼、普拉曲沙、苯达莫司汀、吉西他滨等；CD30阳性患者可选用维布妥昔单抗。此外，也可参考B细胞淋巴瘤中部分二线化疗方案，如DHAP、ESHAP、GemOx、GDP、ICE等。 # 不适合移植的患者 对于身体状态较差、不具备移植条件的患者，治疗通常以单药治疗为主。可考虑的药物包括维布妥昔单抗、戈利昔替尼、普拉曲沙、苯达莫司汀、吉西他滨以及米托蒽醌脂质体等。 但需要强调的是，无论一线还是复发难治阶段，临床试验都是非常重要的治疗选择。尤其对于复发难治PTCL患者，目前现有治疗方案的疗效仍然有限，更需要通过临床研究寻找新的治疗策略。 目前，新药探索仍在进行。例如，HSHR0302联合泽布替尼用于复发难治PTCL的研究正在开展。HSHR0302是一种JAK1抑制剂，其作用机制与戈利司替尼相似。研究数据显示，整体ORR为40%，DCR为80%，该研究仍在持续入组。 总体来看，复发难治PTCL现有治疗的疗效仍然有限。一项系统综述和荟萃分析显示，联合治疗的ORR和CR率相对较高，因此，对于复发难治患者，积极寻找新型治疗策略并参加临床试验仍然非常重要。 造血干细胞移植在外周T细胞淋巴瘤中的地位 PTCL亚型众多，造血干细胞移植的策略不能一概而论。根据2025年EBMT相关移植策略，不同亚型患者在一线缓解后以及复发难治阶段，对自体或异基因造血干细胞移植的选择有所不同。 1）对于滤泡辅助T细胞淋巴瘤、PTCL-NOS和ALK阴性ALCL，如果一线治疗达到完全缓解，可以考虑临床试验或者自体造血干细胞移植进行巩固；如果一线治疗后仅达到部分缓解、疾病难治或者出现复发，而患者仍具备移植条件，则需要考虑以治疗获得的缓解状态作为桥接，进一步进行异基因造血干细胞移植。 2）对于单形性亲上皮性肠道T细胞淋巴瘤（MEITL）以及成人T细胞白血病/淋巴瘤（ATLL）等部分高危类型，如果患者具备移植条件，则一线治疗后就需要较早考虑异基因造血干细胞移植。柳喜洋教授介绍，目前其所在中心也遵循这一治疗策略，对于MEITL患者，一线治疗后即建议符合条件的患者考虑异基因造血干细胞移植。 3）对于结外NK/T细胞淋巴瘤（ENKTL），局限期患者总体预后相对较好，并非一开始就推荐异基因移植；对于晚期、Ⅲ～Ⅳ期患者，在一线治疗取得缓解后，需要考虑异基因造血干细胞移植巩固； 4）肝脾T细胞淋巴瘤（HSTL）预后较差，因此对于符合条件的患者，一线治疗阶段即可考虑异基因造血干细胞移植。 PTCL治疗虽仍充满挑战，但正在不断进步。一线治疗仍以CHOP为基础，维布妥昔单抗联合CHP等新方案已为CD30阳性患者带来明确获益，无化疗方案也为不能耐受化疗的虚弱患者提供了新希望。治疗正从传统化疗走向靶向协同、个体化治疗和长程管理。复发难治阶段仍是难题，但新药和临床试验正在拓展选择。适合移植的患者应根据病理亚型、缓解状态和身体条件，个体化评估自体或异基因造血干细胞移植，争取更深缓解和长期生存。 PTCL治疗已不再是单一方案选择，而需综合病理亚型、CD30状态、分期、治疗反应、体能状态和移植条件制定策略。即使复发难治，也不要放弃希望，积极寻找合适临床试验，可能争取更多治疗机会和更长生存。 专家介绍 柳喜洋 教授 陆道培医院  副主任医师 德国海德堡大学、哥廷根大学医学博士、副主任医师 2017.12-2024.9就职于郑州大学第一附属医院河南省淋巴瘤诊疗中心，曾为河南省淋巴瘤诊疗中心骨干成员，曾赴北京大学第三医院血液科进修半年 中国民族卫生协会医疗科普专业委员会血液肿瘤学组委员 《中国继续医学教育》杂志(ChinaContinuingMedicalEducation，CCME)血液学专业编委， 中国女医师协会罕见病学组委员 河南省研究型医院淋巴瘤协会委员、秘书 发表论文多篇，主持省级课题一项，对初治及复发难治淋巴瘤及多发性骨髓瘤的诊断和治疗具有丰富经验和较深的研究。 擅长淋巴瘤的干细胞移植、CAR-T治疗等。同时擅长噬血细胞综合征的诊治。 END 编辑：行风 | 排版：悠然  | 审核：颖子 声明：本文中涉及的信息仅供淋巴瘤病友及家属交流参考，不作为用药推荐，具体诊疗方案请遵从专业医生的意见或指导。 关于淋巴瘤之家 淋巴瘤之家是中国唯一覆盖全国范围的淋巴瘤患者组织，是国际抗癌联盟、国际淋巴瘤联盟、国际患者联盟、国际慢淋倡导网络的成员，以及国际华氏巨球蛋白血症基金会的合作伙伴。 2011 年由霍奇金淋巴瘤康复病友洪飞创立，其多数工作人员为有过淋巴瘤经历的患者和家属，以“让患者少走弯路，让治愈加速到来”为使命。 在众多淋巴瘤权威医学专家，患者、学者、创新药研发企业们的支持下，淋巴瘤之家成为了被患者认可、提供暖心守护与贴心陪伴的家园。2026年，注册用户已经超过 16万人，每年新增用户超过 2 万人。 关注一下  抗瘤少走弯路